Latest Period
Q2 2026
Security Snapshot
Protara Therapeutics, Inc. - Common Stock (TARA) Institutional Ownership
CUSIP: 74365U107
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
120
Shares (Excl. Options)
46,072,726
Price
$3.82
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TARA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 46,072,726
- Total 13F value
- $176,010,636
- Portfolio coverage rank
- 0%
- Share change
- +1,031,156
- Value change
- -$710,302
- Number of holders
- 120
- Shares outstanding
- 55,913,202
- SEC-reported price per share
- $3.94
- Insider filing price
- $3.94
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TARA - Protara Therapeutics, Inc. - Common Stock is tracked under CUSIP 74365U107.
- 120 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 114 to 120 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $237,379,820 to $176,010,636.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 120 institutions filings for Q2 2026.
Security key
74365U107
Latest holder period
Q2 2026
13F holders
120
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
TARA full holder history
Protara Therapeutics, Inc. SEC filings
Protara Therapeutics, Inc. company facts
Protara Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74365U107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
TARA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Janus Henderson Group Ltd. | 8.4% | -12% | $17,941,428 | -$1,949,354 | 4,696,709 | -9.8% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
| BlackRock, Inc. | 6.3% | +32% | $17,648,661 | +$5,098,459 | 3,387,459 | +41% | BlackRock, Inc. | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC | 5.7% | +12% | $12,221,470 | +$1,689,761 | 3,201,936 | +16% | Millennium Management LLC | 01 Jul 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | -50% | $5,974,448 | -$4,423,642 | 1,971,765 | -43% | RA Capital Management, L.P. | 30 Jun 2025 |
| Opaleye Management Inc. | 4.7% | -12% | $7,473,600 | -$410,400 | 1,730,000 | -5.2% | Opaleye Management, Inc. | 31 Mar 2025 |
| CITADEL ADVISORS LLC | 4.7% | $7,031,811 | 1,627,734 | Kenneth Griffin | 31 Dec 2024 | |||
| Woodline Partners LP | 3.9% | $5,751,035 | 1,331,258 | Woodline Partners LP | 31 Dec 2024 |
As of 30 Jun 2026, 120 institutional investors reported holding 46,072,726 shares of Protara Therapeutics, Inc. - Common Stock (TARA). This represents 82% of the company’s total 55,913,202 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
71%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 8.4% | 4,696,709 | 0% | 0.01% | $17,917,945 |
| BlackRock, Inc. | 6.6% | 3,663,499 | +7.9% | 0% | $13,994,565 |
| MILLENNIUM MANAGEMENT LLC | 5.5% | 3,101,166 | +9.5% | 0.01% | $11,846,454 |
| Velan Capital Investment Management LP | 5.1% | 2,844,652 | +0.35% | 6.7% | $10,866,571 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 2,300,133 | +8.5% | 0% | $8,786,508 |
| Blackstone Inc. | 4.1% | 2,265,514 | 0% | 0.03% | $8,654,263 |
| ORBIMED ADVISORS LLC | 4% | 2,220,000 | 0.16% | $8,480,400 | |
| Sio Capital Management, LLC | 3.4% | 1,921,872 | -2.4% | 1.3% | $7,341,551 |
| ACORN CAPITAL ADVISORS, LLC | 3.1% | 1,752,115 | 0% | 1.8% | $6,693,079 |
| Integral Health Asset Management, LLC | 2.7% | 1,500,000 | -14% | 0.24% | $5,730,000 |
| 5AM Venture Management, LLC | 2.4% | 1,369,782 | 0% | 1.8% | $5,232,567 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,326,246 | +13% | 0% | $5,067,467 |
| CITADEL ADVISORS LLC | 2.2% | 1,232,365 | +15% | 0% | $4,707,635 |
| STATE STREET CORP | 1.9% | 1,068,295 | +6.3% | 0% | $4,080,887 |
| Qube Research & Technologies Ltd | 1.9% | 1,045,516 | +491% | 0% | $3,993,871 |
| Balyasny Asset Management L.P. | 1.8% | 1,026,691 | 0.01% | $3,921,960 | |
| BAKER BROS. ADVISORS LP | 1.7% | 971,614 | 0% | 0.02% | $3,711,565 |
| ADAR1 Capital Management, LLC | 1.7% | 940,512 | 0% | 0.17% | $3,592,756 |
| BANK OF AMERICA CORP /DE/ | 1.6% | 882,179 | -4.7% | 0% | $3,369,924 |
| MARSHALL WACE, LLP | 1.3% | 701,021 | +1282% | 0% | $2,677,900 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 683,230 | +29% | 0% | $2,611,855 |
| NORTHERN TRUST CORP | 0.99% | 552,306 | +47% | 0% | $2,109,809 |
| Point72 Asset Management, L.P. | 0.98% | 548,932 | -52% | 0% | $2,096,920 |
| GOLDMAN SACHS GROUP INC | 0.98% | 546,227 | +37% | 0% | $2,086,587 |
| Catalio Capital Management, LP | 0.93% | 520,148 | -10% | 0.37% | $1,986,965 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 46,072,726 | $176,010,636 | -$710,302 | $3.82 | 120 |
| 2026 Q1 | 45,561,201 | $237,379,820 | +$26,680,746 | $5.21 | 114 |
| 2025 Q4 | 39,827,589 | $212,258,036 | +$73,099,595 | $5.33 | 104 |
| 2025 Q3 | 26,208,473 | $113,965,432 | -$10,353,742 | $4.35 | 79 |
| 2025 Q2 | 29,714,732 | $90,054,436 | +$447,680 | $3.03 | 76 |
| 2025 Q1 | 28,759,849 | $123,767,729 | -$8,349,026 | $4.26 | 59 |
| 2024 Q4 | 29,670,168 | $156,599,526 | +$91,818,405 | $5.28 | 60 |
| 2024 Q3 | 10,445,706 | $19,115,471 | +$384,364 | $1.83 | 33 |
| 2024 Q2 | 10,449,817 | $22,236,374 | +$12,029,265 | $2.08 | 38 |
| 2024 Q1 | 4,570,660 | $18,342,843 | +$911,041 | $4.01 | 34 |
| 2023 Q4 | 4,357,920 | $8,168,237 | -$1,261,027 | $1.88 | 30 |
| 2023 Q3 | 5,117,943 | $8,547,441 | -$31,849 | $1.67 | 31 |
| 2023 Q2 | 5,136,537 | $12,262,078 | -$1,134,644 | $2.39 | 28 |
| 2023 Q1 | 5,503,158 | $16,886,987 | +$77,617 | $3.13 | 28 |
| 2022 Q4 | 5,478,113 | $14,679,319 | -$481,288 | $2.68 | 29 |
| 2022 Q3 | 5,656,228 | $16,718,296 | -$789,370 | $2.96 | 26 |
| 2022 Q2 | 5,927,042 | $18,391,293 | -$2,063,463 | $2.93 | 31 |
| 2022 Q1 | 6,495,468 | $33,192,511 | -$1,990,162 | $5.11 | 34 |
| 2021 Q4 | 6,872,165 | $46,492,675 | +$3,840,591 | $6.75 | 36 |
| 2021 Q3 | 6,311,961 | $43,679,692 | -$8,598,514 | $6.92 | 36 |
| 2021 Q2 | 7,110,843 | $69,259,000 | -$22,850,218 | $9.74 | 38 |
| 2021 Q1 | 8,528,460 | $134,015,000 | -$11,645,346 | $15.74 | 49 |
| 2020 Q4 | 8,775,745 | $212,476,065 | -$5,829,365 | $24.21 | 48 |
| 2020 Q3 | 9,281,283 | $156,208,097 | +$91,825,921 | $16.83 | 44 |
| 2020 Q2 | 3,696,566 | $108,380,809 | +$108,380,809 | $29.32 | 31 |